Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 1Neurofibromatoses 1Neoplasms 1Eye Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lasers × 90 days × Clear all
NCT06643884 2026-03-13

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Aura Biosciences

Phase 2 Recruiting
24 enrolled

Eye Neoplasms, Neoplasms

NCT06934928 2026-03-05

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Massachusetts General Hospital

Phase NA Suspended
10 enrolled
CNS

Neurofibromatosis 1, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon âš¡